Vicore Pharma is a clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases and related indications. The company currently has four development programs: VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is based on a new formulation and delivery route of thalidomide and focuses on the severe, persistent cough associated with IPF. VP03 includes the development of new AT2R agonists. VP04 develops a clinically validated, CBT-based, digital therapeutic for IPF patients. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.